优质白内障手术 (PCS) 市场 (2023)：前 13 个国家分析 (2022-2028)

本报告考察了高级白内障手术 (PCS) 市场，对全球 PCS 手术和产品收入进行了分析，确定了主要趋势，并讨论了未来成功的关键因素。它还包括以下资讯：

• 老花矫正、复曲面、中间节段优化、术后可调IOL、FLACS雷射、FLACS弓形切口、手法角膜缘鬆弛切口、准分子IOL增强术
• 前 13 个国家（美国、日本、中国、巴西、韩国、印度、德国、法国、加拿大、澳洲、西班牙、义大利、英国）PCS 市场概况及详细概况
• 每个国家的执行摘要
• 公立和私立白内障手术选择的成本分析：按国家/地区
• 预测 PCS 手术和製造商收入：按国家/地区
• 预测来自 PCS 程式的提供者收入：按国家/地区
• 各主要国家中纯白内障外科医生、白内障/屈光外科医生和仅屈光外科医生实施的 PCS 手术的百分比
• 各国及全球PCS市场厂商收入市场份额
• 最重要的 PCS 眼科医院和诊所清单：按国家/地区
• 按国家/地区划分的最具影响力的 PCS 关键意见领袖 (KOL) 名单
• 接下来 6 个最重要的 PCS 国家列表（按规模排名）

What's New:

The new "2023 Premium Cataract Surgery Market Report" now features historical analysis of PC-IOL and toric IOL penetration, along with five-year forecasts, for each of the 13 countries covered in the report. The report provides a projection for the impact of recent economics on each of these markets and the elderly populations that account for a majority of premium cataract procedures.

The report examines the strong growth that has occurred in cataract surgery in 2022 and 2023, eliminating much of the COVID-19 backlog. We provide a deeper analysis of the timing and dramatic impact of the loss of PC-IOL and FLACS reimbursement in South Korea.

The new report also features more than 20 premium IOL product surveys in the United States and Western Europe; lists the many new PC-IOLs launched at the 2023 ESCRS congress; and expands on the list of premium cataract surgery centers by country.

The "2023 Premium Cataract Surgery Market Report" is designed to provide insights into the most important premium cataract surgery (PCS) markets in the world. We've selected and profiled 13 countries that collectively account for 84 percent of global PCS manufacturer revenue and provided a deep dive into each of these markets. Ranked by 2022 PCS manufacturer revenue, they are: the United States, China, South Korea, Japan, Brazil, Germany, Canada, Australia, France, India, Spain, the UK, and Italy.

For each of these countries, the report focuses on specific characteristics considered vital to the understanding of the opportunities in each country for companies planning to market premium cataract surgery devices or looking to assess the value of each market.

Contents:

The report offers an in-depth examination of the 2023 premium cataract surgery (PCS) market. It includes analysis of the global PCS procedure and product revenue, identification of important trends, and discussion of key factors for future success. The following information is also included:

• Presbyopia-correcting, toric, intermediate-optimized, and post-op adjustable IOLs, FLACS lasers, FLACS arcuate incisions, manual limbal relaxing incisions, and excimer IOL enhancements.

• Snapshots and in-depth profiles of the top 13 PCS markets: the US, Japan, China, Brazil, South Korea, India, Germany, France, Canada, Australia, Spain, Italy, and the UK.

• Individual country executive summary.

• Analysis of the cost of public and private cataract surgery options by country.

• Forecasts for PCS procedures and manufacturer revenue by country.

• Forecasts for provider revenue resulting from PCS procedures by country.

• Percentage of PCS procedures performed in each key country by cataract-only, cataract/refractive, and refractive-only surgeons.

• Manufacturer revenue market shares of the PCS market in each country and globally.

• Listing of the most important PCS eye hospitals and clinics by country.

• Listing of the most influential PCS key opinion leaders (KOLs) by country.

• A list of the next six most important PCS countries ranked by size.

Author Profile:

William Freeman

Bill Freeman has more than 35 years of experience developing, manufacturing, and marketing cataract surgery products. He has held key executive positions at four firms that produce ophthalmic surgical devices.

Bill's career in ophthalmology began in the 1970s. As president of Cavitron Surgical Systems, he worked with Dr. Charles Kelman in developing and marketing the world's first phacoemulsifier system. While highly controversial in the 1970s, phacoemulsification gradually became the preferred cataract removal technique in the early 1980s. For many years, Cavitron led the cataract instrumentation market.

CooperVision purchased Cavitron in the early 1980s, and Bill joined the company as president of the surgical division. CooperVision expanded its product line to include a wide variety of cataract surgical products-IOLs, viscoelastic solutions, disposable devices, lasers, and custom packs-and became the market leader in many product categories.

In 1989, Alcon acquired CooperVision in an effort to build a strong presence in cataract surgical devices. Bill joined Alcon as general manager of the Irvine Technology Center, where a number of the company's cataract devices, including the Legacy 20000 phacoemulsifier and a broad line of disposable items, were designed and manufactured.